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The biopharmaceutics and pharmacokinetics of [D-alaq D-leuslenkephalin (YdAGFdL) 
was investigated after six intravenous, oral, and nasal administration in a randomized 
cross-over fashion in two dogs. Following administration of [sH]YdAGFdL, blood 
samples were collected from the forearm vein over 90 min and assayed by radiometric 
thin layer chromatography for intact YdAGFdL and tyrosine (metabolite), respectively. 
Data were analyzed by non-compartmental pharmacokinetic methods. For each study, 
the areas under YdAGFdL and tyrosine curves (AUC) from time zero to 90 min were 
estimated by the trapezoidal rule. After intravenous dosings of 2.8 ug, total body 
clearance, volume of distribution at steady state, half-life of elimination phase, and 
mean residence time were 0.65 f 0.16 (S.E.) I/min, 6.95 +1.21 I, 22.3 + 3.4 min, and 
11.7 + 1.6 min, respectively. Time to reach the maximum concentration (Tmax) for 
YdAGFdL after nasal administration was 7.3 f 0.8 min. The Tmax for tyrosine after 
intravenous, oral, and nasal administrations were 5.4 + 2.5, 9.7+ 2.3, and 11.4 + 3.4 
min, respectively. Mean bioavailability after oral (11.2 ug) and nasal (2.8 ug) 
administration were less than 0.5% (based on the detection limit) and 5.9 f 4.8%, 
respectively. The fractions of the tyrosine AUC over the AUC of total radioactivity in 
blood following intravenous, oral, and nasal administration were 0.071, 0.137, and 
0.048, respectively. These results indicate that even the ‘stabilized’ peptide is 
extensively metabolized during absorption in the GI tract resulting in the poor oral 
systemic availability. The absorption of small peptide drugs could be improved 
significantly (p c 0.05) after nasal administration. Application of these results to the 
delivery of peptide drugs will be discussed. 
